Home Newsfeeds Deutsche Bank Maintains Buy on Uber Technologies, Raises Price Target to $44

Deutsche Bank Maintains Buy on Uber Technologies, Raises Price Target to $44

Deutsche Bank analyst Benjamin Black maintains Uber Technologies (NYSE:UBER) with a Buy and raises the price target from $42 to $44.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Deutsche Bank analyst Benjamin Black maintains Uber Technologies (NYSE:UBER) with a Buy and raises the price target from $42 to $44.

TopBuild’s Future Prospects: Analyst Highlights Single-Family Market Rebound And Growth In Commercial/Industrial Segment

By Nabaparna Bhattacharya

August 4, 2:31 PM

Truist Securities analyst Keith Hughes reiterated a Buy rating on TopBuild Corp. (NYSE: BLD),

BLD

UroGen Pharma Ltd. Retrospective Study Reveals Lower Stricture Rate And Comparable Oncological Outcomes With Antegrade Administration Of JELMYTO Versus Retrograde Administration

By Happy Mohamed

June 20, 8:14 AM

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the

URGN

Cowen & Co. Maintains Outperform on Greenbrier Companies, Lowers Price Target to $47

By Benzinga Newsdesk

July 13, 9:26 AM

Cowen & Co. analyst Matt Elkott maintains Greenbrier Companies (NYSE:GBX) with a Outperform and lowers the price target from $54 to $47.

GBX

Barclays Maintains Overweight on Excelerate Energy, Lowers Price Target to $27

By Benzinga Newsdesk

July 20, 8:15 AM

Barclays analyst Marc Solecitto maintains Excelerate Energy (NYSE:EE) with a Overweight and lowers the price target from $33 to $27.

Deutsche Bank Maintains Buy on Uber Technologies, Raises Price Target to $44

Related Posts

TopBuild’s Future Prospects: Analyst Highlights Single-Family Market Rebound And Growth In Commercial/Industrial Segment

UroGen Pharma Ltd. Retrospective Study Reveals Lower Stricture Rate And Comparable Oncological Outcomes With Antegrade Administration Of JELMYTO Versus Retrograde Administration

Cowen & Co. Maintains Outperform on Greenbrier Companies, Lowers Price Target to $47

Barclays Maintains Overweight on Excelerate Energy, Lowers Price Target to $27